BRPI1009460A2 - domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra. - Google Patents

domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra.

Info

Publication number: BRPI1009460A2
Authority: BR; Brazil
Prior art keywords: antibody; binding domain; sample; detecting; cancer cells
Prior art date: 2009-03-16

Application number

BRPI1009460A

Other languages

English (en)

Inventor

Adam William Clarke

Anthony Gerard Doyle

Matthew Pollard

Norbert Alexander Kienzle

Philip Anthony Jennings

Original Assignee

Cephalon Australia Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-16

Filing date

2010-03-16

Publication date

2016-03-01

2009-03-16 Priority claimed from AU2009901129A external-priority patent/AU2009901129A0/en

2010-03-16 Application filed by Cephalon Australia Pty Ltd filed Critical Cephalon Australia Pty Ltd

2016-03-01 Publication of BRPI1009460A2 publication Critical patent/BRPI1009460A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI1009460A 2009-03-16 2010-03-16 domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra. BRPI1009460A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US16068209P	2009-03-16	2009-03-16
AU2009901129A AU2009901129A0 (en)		2009-03-16	Humanised antibodies with anti-tumour activity
US25851709P	2009-11-05	2009-11-05
PCT/AU2010/000298 WO2010105290A1 (en)	2009-03-16	2010-03-16	Humanised antibodies with anti-tumour activity

Publications (1)

Publication Number	Publication Date
BRPI1009460A2 true BRPI1009460A2 (pt)	2016-03-01

Family

ID=42739039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1009460A BRPI1009460A2 (pt)	2009-03-16	2010-03-16	domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra.

Country Status (18)

Country	Link
US (2)	US8470320B2 (pt)
EP (2)	EP2408820A4 (pt)
JP (1)	JP5746134B2 (pt)
KR (1)	KR20110129935A (pt)
CN (1)	CN102395604B (pt)
AU (1)	AU2010225448B2 (pt)
BR (1)	BRPI1009460A2 (pt)
CA (1)	CA2769276A1 (pt)
EA (1)	EA024695B1 (pt)
IL (1)	IL214840A (pt)
MA (1)	MA33194B1 (pt)
MX (1)	MX2011009704A (pt)
NZ (2)	NZ594668A (pt)
SG (1)	SG173577A1 (pt)
TN (1)	TN2011000417A1 (pt)
UA (1)	UA108349C2 (pt)
WO (1)	WO2010105290A1 (pt)
ZA (1)	ZA201105875B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2010314798B2 (en) *	2009-11-05	2013-10-24	Teva Pharmaceuticals Australia Pty Ltd	Treatment of cancer involving mutated KRAS or BRAF genes
EP3559049B1 (en)	2011-10-28	2025-06-11	Teva Pharmaceuticals Australia Pty Ltd	Polypeptide constructs and uses thereof
US9447193B2 (en) *	2013-03-24	2016-09-20	Development Center For Biotechnology	Methods for suppressing cancer by inhibition of TMCC3
FI3677591T3 (fi)	2013-04-29	2023-04-03	Teva Pharmaceuticals Australia Pty Ltd	Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
US11117975B2 (en)	2013-04-29	2021-09-14	Teva Pharmaceuticals Australia Pty Ltd	Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
UA119352C2 (uk)	2014-05-01	2019-06-10	Тева Фармасьютикалз Острейліа Пті Лтд	Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EA037749B1 (ru)	2014-10-29	2021-05-18	Тева Фармасьютикалз Острэйлиа Пти Лтд	ВАРИАНТЫ ИНТЕРФЕРОНА 2b
CN112710843B (zh) *	2020-12-16	2022-11-04	江苏伟禾生物科技有限公司	一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225539A (en) *	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8928874D0 (en) *	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US6042828A (en)	1992-09-07	2000-03-28	Kyowa Hakko Kogyo Co., Ltd.	Humanized antibodies to ganglioside GM2
US6277375B1 (en)	1997-03-03	2001-08-21	Board Of Regents, The University Of Texas System	Immunoglobulin-like domains with increased half-lives
ES2434961T5 (es)	1998-04-20	2018-01-18	Roche Glycart Ag	Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US6998267B1 (en)	1998-12-09	2006-02-14	The Dow Chemical Company	Method for manufacturing glycoproteins having human-type glycosylation
KR101077001B1 (ko)	1999-01-15	2011-10-26	제넨테크, 인크.	효과기 기능이 변화된 폴리펩티드 변이체
AU2001276842B2 (en) *	2000-06-28	2007-04-26	Glycofi, Inc.	Methods for producing modified glycoproteins
PT1355919E (pt) *	2000-12-12	2011-03-02	Medimmune Llc	Moléculas com semivida longa, composições que as contêm e suas utilizações
IL166244A0 (en) *	2001-07-12	2006-01-15	Jefferson Foote	Super humanized antibodies
US20040132101A1 (en) *	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US7317091B2 (en) *	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US7217797B2 (en) *	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0410627D0 (en) *	2004-05-12	2004-06-16	Scancell Ltd	Specific binding members
NZ563213A (en) *	2005-06-01	2009-07-31	Micromet Ag	Anti-IL2 antibodies
EP1878747A1 (en)	2006-07-11	2008-01-16	greenovation Biotech GmbH	Glyco-engineered antibodies

2010
- 2010-03-16 EP EP10752991A patent/EP2408820A4/en not_active Withdrawn
- 2010-03-16 NZ NZ594668A patent/NZ594668A/xx not_active IP Right Cessation
- 2010-03-16 UA UAA201112103A patent/UA108349C2/uk unknown
- 2010-03-16 CN CN201080011960.8A patent/CN102395604B/zh not_active Expired - Fee Related
- 2010-03-16 AU AU2010225448A patent/AU2010225448B2/en not_active Ceased
- 2010-03-16 EP EP11183705.0A patent/EP2433967A3/en not_active Withdrawn
- 2010-03-16 SG SG2011056751A patent/SG173577A1/en unknown
- 2010-03-16 CA CA2769276A patent/CA2769276A1/en not_active Abandoned
- 2010-03-16 WO PCT/AU2010/000298 patent/WO2010105290A1/en not_active Ceased
- 2010-03-16 NZ NZ600915A patent/NZ600915A/xx not_active IP Right Cessation
- 2010-03-16 BR BRPI1009460A patent/BRPI1009460A2/pt not_active IP Right Cessation
- 2010-03-16 JP JP2012500004A patent/JP5746134B2/ja not_active Expired - Fee Related
- 2010-03-16 US US12/725,192 patent/US8470320B2/en not_active Expired - Fee Related
- 2010-03-16 MA MA34251A patent/MA33194B1/fr unknown
- 2010-03-16 MX MX2011009704A patent/MX2011009704A/es active IP Right Grant
- 2010-03-16 EA EA201171133A patent/EA024695B1/ru not_active IP Right Cessation
- 2010-03-16 KR KR1020117023016A patent/KR20110129935A/ko not_active Ceased
2011
- 2011-08-11 ZA ZA2011/05875A patent/ZA201105875B/en unknown
- 2011-08-12 TN TN2011000417A patent/TN2011000417A1/fr unknown
- 2011-08-25 IL IL214840A patent/IL214840A/en not_active IP Right Cessation
2013
- 2013-05-21 US US13/898,666 patent/US8901279B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20100297134A1 (en)	2010-11-25
US8901279B2 (en)	2014-12-02
CA2769276A1 (en)	2010-09-23
ZA201105875B (en)	2012-11-28
SG173577A1 (en)	2011-09-29
MX2011009704A (es)	2011-09-28
EA201171133A1 (ru)	2012-03-30
US8470320B2 (en)	2013-06-25
WO2010105290A1 (en)	2010-09-23
NZ600915A (en)	2013-09-27
AU2010225448B2 (en)	2013-10-24
EP2433967A3 (en)	2013-05-01
UA108349C2 (uk)	2015-04-27
AU2010225448A1 (en)	2011-09-08
MA33194B1 (fr)	2012-04-02
CN102395604B (zh)	2015-11-25
EP2408820A4 (en)	2013-01-23
EP2433967A2 (en)	2012-03-28
EP2408820A1 (en)	2012-01-25
IL214840A (en)	2015-11-30
EA024695B1 (ru)	2016-10-31
TN2011000417A1 (en)	2013-03-27
US20130280246A1 (en)	2013-10-24
IL214840A0 (en)	2011-11-30
CN102395604A (zh)	2012-03-28
JP5746134B2 (ja)	2015-07-08
NZ594668A (en)	2012-10-26
JP2012520329A (ja)	2012-09-06
KR20110129935A (ko)	2011-12-02

Legal Events

Date	Code	Title
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-01-09	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-05-02	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2021-06-01	B350	Update of information on the portal [chapter 15.35 patent gazette]

Publication	Publication Date	Title
BRPI0923199A2 (pt)	2016-02-16	métodos e composições para detecção de anticorpos com fixação de complemento.
BRPI1009460A2 (pt)	2016-03-01	domínio de ligação do anticorpo, anticorpo, uso de um domínio de ligação ou anticorpo, método para detectar a presença de células cancerígenas em uma amostra.
BRPI0920586A2 (pt)	2017-05-30	dispositivo de separacao para uso na separacao ,caracterizacao e/ou identificacao de micro-organismos.
BRPI0913733A2 (pt)	2015-08-18	Artigos para detecção de células, dispositivo de aquisição de amostra, kit e métodos para detecção de células
EP2454587A4 (en)	2012-12-12	DEVICES, METHODS, AND KITS FOR DETERMINING ANALYZ CONCENTRATIONS
BRPI0819280A2 (pt)	2015-05-19	Preparação de amostra para amostragem ambiental
DK2050765T3 (da)	2012-09-17	Fremgangsmåder til anvendelse ved til mennesker tilpassede antistoffer
BRPI1006134A2 (pt)	2016-02-23	anticorpo ou um fragmento funcional do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento funcional do mesmo, polinucleotídeo, vetor, e, célula hospedeira transformada.
IL233095A0 (en)	2014-07-31	Ratio based biomarkers and methods of use thereof
WO2009129505A3 (en)	2010-02-18	Compositions, methods, and kits using synthetic probes for determining the presence of a target nucleic acid
BR112012003809A2 (pt)	2019-09-24	anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
IL213116B (en)	2018-11-29	Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
PT2427212T (pt)	2017-11-20	Anticorpos anti-cd100 e métodos para utilização dos mesmos
WO2009037572A3 (en)	2009-11-26	Biomarker combinations for colorectal cancer
EP2255183A4 (en)	2012-05-30	DOSAGE PREPARATION PLATES, FLUID ASSAY ANALYSIS AND PREPARATION SYSTEMS, AND DOSAGE PREPARATION AND ANALYSIS METHODS
BRPI0918101A2 (pt)	2015-11-24	método para medir a troponina i em uma amostra, cartucho para ser utilizado em um dispositivo de ensaio e uso
BRPI0906478A2 (pt)	2015-11-24	anticorpo anti-nr10 e uso do mesmo
BR112014012590A8 (pt)	2017-12-19	Anticorpos anti-cd98 e métodos de uso dos mesmos
BRPI0907174A2 (pt)	2015-07-14	Métodos para prevenção ou reparação de depósito de xantana
BRPI1015922A2 (pt)	2016-04-26	sistemas e métodos para testar analitos
BR112015009901A2 (pt)	2017-07-11	elementos de ensaio , material reagente e método para a determinação dos primeiro e segundo analitos em uma amostra.
BR112013008255A2 (pt)	2018-09-25	anticorpo isolado ou um fragmento funcional do mesmo, uso de um anticorpo isolado ou de um fragmento funcional do mesmo, composição farmacêutica, polinucleotídeo, vetor, célula transformada, e, método para produzir anticorpo
BRPI0912426A2 (pt)	2017-06-06	método executado por computador, computador, e sistema para uso com poço
BRPI0820721A2 (pt)	2015-06-16	Reagentes e métodos para detectar analitos
BRPI1013896A2 (pt)	2015-08-25	Célula de levedura, e, métodos para produzir um composto isoprenóide e para detectar em uma amostra biológica a presença ou ausência de uma célula microbiana geneticamente.